发明名称 |
CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS |
摘要 |
The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. |
申请公布号 |
CA2350064(C) |
申请公布日期 |
2012.05.08 |
申请号 |
CA19992350064 |
申请日期 |
1999.11.09 |
申请人 |
IDEC PHARMACEUTICALS CORPORATION |
发明人 |
GRILLO-LOPEZ, ANTONIO J.;LEONARD, JOHN E. |
分类号 |
A61K39/395;A01N1/00;A01N1/02;A01N63/00;A61K39/00;A61P35/00;A61P35/02;A61P37/06;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|